Skip to main content

Eli Lilly and Company Europe revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Europe revenue at Eli Lilly and Company came to $4.5B for the quarter to 30 Sep 2026, up 27.5% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$1.3BDec 2023$1.4BMar 2024$1.4BJun 2024$1.6BSep 2024$2.4BDec 2024$2.4BMar 2025$2.6BJun 2025$3.5BSep 2025$3.1BDec 2025$3.6BMar 2026$4.1BJun 2026$4.5BSep 2026
Eli Lilly and Company Europe revenue, every reported period
Period endingEurope revenueChange on a yearFiled
30 Sep 2026$4.5Bup 27.5%29 Oct 2026
30 Jun 2026$4.1Bup 59.9%5 Aug 2026
31 Mar 2026$3.6Bup 52.6%30 Apr 2026
31 Dec 2025$3.1Bup 26.5%12 Feb 2026
30 Sep 2025$3.5Bup 114.8%30 Oct 2025
30 Jun 2025$2.6Bup 83.4%7 Aug 2025
31 Mar 2025$2.4Bup 65.8%1 May 2025
31 Dec 2024$2.4Bup 83.0%19 Feb 2025
30 Sep 2024$1.6Bdown 36.6%30 Oct 2024
30 Jun 2024$1.4Bup 19.2%8 Aug 2024
31 Mar 2024$1.4Bup 32.1%30 Apr 2024
31 Dec 2023$1.3Bup 24.5%21 Feb 2024
30 Sep 2023$2.6Bup 143.1%2 Nov 2023
30 Jun 2023$1.2Bup 6.9%8 Aug 2023
31 Mar 2023$1.1Bup 2.2%27 Apr 2023
31 Dec 2022$1.1Bdown 6.3%22 Feb 2023
30 Sep 2022$1.1Bdown 3.8%1 Nov 2022
30 Jun 2022$1.1Bdown 9.0%4 Aug 2022
31 Mar 2022$1.1Bdown 19.2%29 Apr 2022
31 Dec 2021$1.1Bdown 4.7%23 Feb 2022
30 Sep 2021$1.1Bup 5.0%27 Oct 2021
30 Jun 2021$1.2Bup 38.6%3 Aug 2021
31 Mar 2021$1.3Bup 24.5%30 Apr 2021
31 Dec 2020$1.2Bup 18.8%17 Feb 2021
30 Sep 2020$1.0Bup 13.4%28 Oct 2020
30 Jun 2020$873.0Mdown 5.9%31 Jul 2020
31 Mar 2020$1.1Bup 17.8%1 May 2020
31 Dec 2019$1.0Bup 8.0%19 Feb 2020
30 Sep 2019$923.4Mup 3.7%25 Oct 2019
30 Jun 2019$928.2Mdown 1.4%2 Aug 2019
31 Mar 2019$900.3Mup 4.2%2 May 2019
31 Dec 2018$938.0Mdown 12.0%19 Feb 2019
30 Sep 2018$890.3Mdown 12.5%6 Nov 2018
30 Jun 2018$941.0Mdown 2.3%25 Jul 2018
31 Mar 2018$864.2Mdown 3.7%27 Apr 2018
31 Dec 2017$1.1B—20 Feb 2018
30 Sep 2017$1.0B—27 Oct 2017
30 Jun 2017$963.6M—28 Jul 2017
31 Mar 2017$897.0M—1 May 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Cardiometabolic Health revenue · Zepbound revenue · Mounjaro revenue · Oncology revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Rest of world revenue · China revenue · Japan revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.